Lantheus Secures FDA Nod for PYLARIFY TruVu, Aims to Boost Prostate Cancer Imaging Supply

Event summary

  • Lantheus received FDA approval for PYLARIFY TruVu, a new formulation of its PSMA PET imaging agent PYLARIFY, on March 6, 2026.
  • PYLARIFY TruVu is designed to enhance product stability, enabling larger batch sizes and broader geographic reach.
  • The new formulation is expected to launch in 4Q 2026, with a phased geographic rollout.
  • PYLARIFY has been used in over 760,000 scans since its approval in May 2021.

The big picture

Lantheus' FDA approval for PYLARIFY TruVu comes as prostate cancer incidence rates continue to rise, with nearly 334,000 new cases expected in 2026. The new formulation addresses a critical need for greater access to high-quality diagnostic tools, aligning with broader industry trends toward precision medicine and improved patient outcomes. The strategic move positions Lantheus to capitalize on growing demand while enhancing its operational efficiency.

What we're watching

Supply Chain Efficiency
Whether PYLARIFY TruVu's enhanced manufacturing capabilities will improve supply chain dependability and operating leverage.
Market Adoption
The pace at which healthcare providers transition from PYLARIFY to PYLARIFY TruVu and the potential impact on patient access.
Regulatory Compliance
How Lantheus manages the technology transfer across its PET manufacturing facilities to ensure seamless FDA approval for each site.